COPD Trial, Recruiting (NCT07052396)

COPD Trial, Recruiting NCT07052396 Sponsor: Sanofi Condition: COPD

Printed from Voxsanity (voxsanity.com.au) — NCT07052396 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Copd

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be willing and able to give your agreement (consent) for your anonymised health information to be used in this study.
You must be an adult (18 years of age or older).
You have COPD that is not well controlled, even though you are already using a combination of long-acting inhaler medicines (or a two-medicine combination if steroids are not right for you), and your blood tests show higher-than-normal levels of a type of white blood cell called eosinophils.
Your doctor has recently decided to start you on a medicine called dupilumab for your COPD, based on the approved guidelines for that medicine, separately from your involvement in this study.

Who may not be able to join:

You are not considered suitable for dupilumab treatment according to its official approved guidelines.
You are currently taking part in, or have taken part in, another research study within the last 12 months that your doctor thinks could affect the results of this study.
You have any health condition — either short-term or long-term — that your doctor believes would make it hard for you to fill in questionnaires, take part in the study, or that could affect how the results are understood (confirm with trial site).
You were admitted to hospital because of a COPD flare-up (worsening) within the 4 weeks before joining the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 800-633-1610

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07052396

Sponsor: Sanofi

Phase: Not Applicable

Status: Recruiting

Condition: COPD

Trial contact: 800-633-1610

More information: https://clinicaltrials.gov/study/NCT07052396

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be willing and able to give your agreement (consent) for your anonymised health information to be used in this study.
You must be an adult (18 years of age or older).
You have COPD that is not well controlled, even though you are already using a combination of long-acting inhaler medicines (or a two-medicine combination if steroids are not right for you), and your blood tests show higher-than-normal levels of a type of white blood cell called eosinophils.
Your doctor has recently decided to start you on a medicine called dupilumab for your COPD, based on the approved guidelines for that medicine, separately from your involvement in this study.

Who may not be able to join:

You are not considered suitable for dupilumab treatment according to its official approved guidelines.
You are currently taking part in, or have taken part in, another research study within the last 12 months that your doctor thinks could affect the results of this study.
You have any health condition — either short-term or long-term — that your doctor believes would make it hard for you to fill in questionnaires, take part in the study, or that could affect how the results are understood (confirm with trial site).
You were admitted to hospital because of a COPD flare-up (worsening) within the 4 weeks before joining the study.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Sanofi

Registry

ClinicalTrials.gov

Start date

1 July 2025

Est. completion

1 July 2029

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Change from Baseline in COPD Assessment Test (CAT) Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov